Abstract
Acquisition of drug resistance is one of the major hurdles in the treatment of several cancers including ovarian carcinoma. There exist very few models that aid in understanding the mechanism of drug resistance in cancer cells. Carboplatin is administered as a first line chemotherapeutic drug in the treatment of ovarian cancer. Majority of ovarian cancer patients respond well to chemotherapy in the initial stages, but 60-70% report recurrence post therapy. The underlying molecular mechanisms contributing to resistance to therapy remain elusive. Establishing a clinically relevant in vitro tumor model that could closely mimic the drug resistance pattern in the patient would provide an opportunity to understand drug resistance. The present study focuses on generating a clinically relevant drug resistant model of ovarian cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Journal of Cancer Science and Clinical Therapeutics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.